Avastin for PDR (Proliferative Diabetic Retinopathy)
| Status: | Completed |
|---|---|
| Conditions: | Ocular, Diabetes |
| Therapuetic Areas: | Endocrinology, Ophthalmology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 11/18/2012 |
| Start Date: | June 2009 |
| End Date: | July 2012 |
| Contact: | Elliott Sohn, MD |
| Email: | elliott-sohn@uiowa.edu |
| Phone: | 319-356-8350 |
Effect of Pre-operative Adjunctive Anti-VEGF on Growth Factors in Severe Proliferative Diabetic Retinopathy Requiring Surgical Management
The purpose of this study is to determine the effect of anti-VEGF drug (Avastin)
adminstration in eyes prior to surgical treatment for Traction retinal detachment (TRD) in
patients with Proliferative Diabetic Retinopathy (PDR).
Traction retinal detachment (TRD) due to proliferative diabetic retinopathy is a blinding
disease caused by contraction of fibrovascular proliferation, treatment of which is limited
to surgery. Fibrosis and neovascularization are both associated with high levels of
connective tissue growth factor (CTGF) and vascular endothelial growth factor (VEGF) in the
eye. Small, nonrandomized studies have suggested that pre-operative adjunctive anti-VEGF
administration may reduce intra- and post-operative complications and provide visual benefit
in patients with this condition.
Inclusion Criteria:
- Active fibrovascular proliferation due to PDR with TRD given pre-operative clearance
for pars plana vitrectomy (PPV) and TRD repair.
Exclusion Criteria:
- Dense vitreous hemorrhage
- Inability to follow-up for surgery within 3-7 days after intravitreal injection
- History of stroke, thromboembolic event, or heart attack within the last 6 months
- Less than 18 years of age
- Pregnancy
We found this trial at
1
site
University of Southern California The University of Southern California is one of the world’s leading...
Click here to add this to my saved trials
